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Copy number variations (CNV) represent a significant proportion of the genetic differences 6 between individuals and many CNVs associate causally with syndromic disease and clinical 7
outcomes. Here, we characterize the landscape of copy number variation and their phenome-8 wide effects in a sample of 472,228 array-genotyped individuals from the UK Biobank. In 9 addition to population-level selection effects against genic loci conferring high-mortality, we 10 describe genetic burden from syndromic and previously uncharacterized CNV loci across nearly 11 2,000 quantitative and dichotomous traits, with separate analyses for common and rare classes 12 of variation. Specifically, we highlight the effects of CNVs at two well-known syndromic loci 13
16p11.2 and 22q11.2, as well as novel associations at 9p23, in the context of acute coronary 14 artery disease and high body mass index. Our data constitute a deeply contextualized portrait of 15 population-wide burden of copy number variation, as well as a series of known and novel 16 dosage-mediated genic associations across the medical phenome. 17 18 Introduction: 19 20 Copy number variants (CNV) are a class of structural variation often defined as large deletions 21 or duplications of at least 1 kilobase (kb) of genomic sequence. CNVs exhibit substantial 22 variability in both size and frequency in the population and have been implicated across a 23 variety of common and rare health outcomes 1 . Regional deletion and duplication syndromes 24
have also been described at many loci, clustering near microsatellite repeats or areas of 25 segmental duplication which may potentiate non-allelic homologous recombination 2 . For 26 example, CNV-based architectures for neuropsychiatric (e.g. autism spectrum disorder), 27
developmental (e.g. 16p11.2) 3,4 , and syndromic cardiac disease (e.g. 22q11.2) 5 phenotypes 28 have been well established. 29 30
Despite a growing body research on CNV-related syndromes and disease etiologies, large-31 scale studies of CNV effects have been limited by their rarity in the general population. 32
However, burden testing methods which address this rarity by pooling observed variation across 33 gene regions have yielded reproducible associations in the context of congenital heart disease 34 and various neurocognitive outcomes 6,7 . Moreover, as studies which include either microarray or 35 NGS-based genotype data have grown in size and scope, it has become possible to describe 36 the distribution of CNVs at kilobase-level resolution in the general population 8, 9 . Furthermore, 37
the aggregation of richly annotated phenotype data in biobanks has diversified the set of 38 phenotypes available for well-powered association studies, and allows for more precise 39 characterization of syndromic CNV-associated disease 10,11,12 . 40 41 We here describe the landscape of copy number variation and their associations with 1,937 42 phenotypes in a cohort of 472 quality control. We also observe heavy-tailed distributions in size and allele count of CNVs, with 57 average CNV length ~226kb and the majority of called variants singleton in the cohort ( Figure  58 1a,b). This translates to notable burden of variation for nearly all individuals, with 439,464 59 (93.1%) of the individuals possessing at least one CNV detectable at kilobase-resolution 60 (Figure 1c,1d ). Among individuals with at least one CNV, we estimate an average burden of 5.5 61 variants covering >200kb of genomic sequence (median 3 variants affecting ~100kb, Figure  62 1c,d). While in-line with previous reports 8 , these estimates of individual-level burden are likely 63 conservative, as regions where array markers are sparse or missing limit the accuracy of variant 64
calling. Furthermore, we are unable to call smaller (<1kb) variants due to inconsistent marker 65 density across all chromosomal regions on the Axiom and BiLEVE UK Biobank genotyping 66 arrays. This limitation is visible in the histogram of called CNV lengths ( Figure 1a ); we call 67 substantially fewer variants on the order of hundreds of base-pairs than on the order of 68 thousands. 69 70
We also observe a highly non-uniform burden of variation across genomic position, with 71 breakpoints most common near the ends of chromosomes, and at known regions of segmental 72 duplication ( Figure 1e ). Among them are 1p36, 8q24.3, 9q34.3, and 19q13, all of which have 73 associated microdeletion syndromes causing developmental delay with uniquely characteristic 74 growth patterns [16] [17] [18] [19] . Other CNV-hotspots like 6p21.33, which contains the major 75 histocompatibility complex protein gene family, may be influenced by high marker density (in 76 this case for HLA allelotyping) in addition to these biological features which underlie structural 77 mutagenesis. However, these loci do not categorically correspond to areas where structural 78 variation is commonly observed in the population ( Figure S1 ). For example, 1p36 and 19q13 are 79 also the respective sites of common CNVs overlapping RHD and FUT2 (Rhesus and Lewis 80 blood groups), but there are no such common variants within the telomeric 16p13 cytoband. 81 We estimate gene-level intolerance to structural variation by adapting a method for estimating 87 regional selective constraint 8 . Relative to the general population, the volunteers within the UK 88
Biobank are described to have a "healthy-cohort" enrollment bias 20 and were enrolled between 89 the ages of 40 to 69, which informs our findings. Within the tail of positive constraint z-scores, 90
which indicate the strongest intolerance to structural variation, we observe enrichment for genes 91 which cause early onset diseases, particularly cancer. Among the top fifteen constrained genes 92 ( Selections from the most highly constrained pathways from Gene Ontology Consortium 28 98 resources (Table 2 ) also suggest strong intolerance to CNV for genes involved with core 99 biological processes like protein binding, cellular structural integrity (keratinization), 100 development (growth hormone receptor binding), and immune regulation (natural killer cell 101 activation). Similar results at the gene-and pathway-level are observed for deletion-specific 102 (Table S1 ,S2), whereas duplication-specific analysis suggests autoimmune-related 103 genes and pathways are most strongly intolerant to dosage effects (Table S1,S2). These results 104 indicate strong selective effects occurring prior to enrollment in the UK Biobank during childhood 105 and early adulthood against loss of function variation in core developmental, metabolic, and 106 tumor-suppressing genes, and against dosage-altering variation in immune-related genes. 107 108
Association testing identifies CNVs at novel and syndromic loci 109 110
We compute genome-wide associations across 1,893 phenotypes for 8,274 common CNVs 111 observed at 0.005% allele frequency (1 in 20,000) in our cohort, using regression as 112
implemented in the analysis software PLINK 29 . We also perform L1-regularized regression for 113 rare-variant burden tests, pooled by gene. For these tests, we measure the net effect of rare 114
CNVs (AF < 0.1%) overlapping within 10kb of the gene region as defined by HGNC 30 for 7,614 115 protein coding genes with at least 5 individuals affected by such a variant. A complete list of 116 phenotypes analyzed is available in Table S3 . Here, we describe representative results for one 117 common disease and one quantitative measure with established genetic risk factors and large 118 sample sizes in UK Biobank: acute coronary artery disease (CAD) and body mass index (BMI). 119 120
For Acute CAD, we identify one statistically significant (p < 6⨉10 -6 ) association after Bonferroni 121 correction for the common CNV GWAS: an intergenic deletion at chromosome 9p23. Intergenic 122 variants at the 9p21 locus have been implicated in previous association studies of blood-based 123 biomarkers relevant to cardiac outcomes, specifically, decreases in hematocrit and hemoglobin 124 concentration 31 , as well as carotid plaque burden 32 . A recent meta-analysis 33 using data from 125 UK Biobank and CARDIoGRAMplusC4D identified a lead variant in the vicinity of this locus 126 (rs2891168) associated with 6% unit increase in risk for similarly defined coronary artery 127 disease. However, the CNV we here identify confers an estimated 12.4-fold increased risk 128 (95%CI: 4.3-35.9, p=3.6⨉10 -6 ) and is at least 2Mb distant from the nearest SNPs (rs10961206)  129 at genome-wide significance near the 9p21/9p23 locus in the meta-analysis. This and the 130 absence of linkage between the 9p23 CNVs and rs10961206 (r = 0.013) are suggestive of 131 independent effects. 132 133
Gene-level burden testing of rare CNVs in individuals with CAD implicates LDLRAD3, a member 134 of the low density lipoprotein (LDL) receptor family. CNVs called in this gene are predominantly 135 deletions affecting the coding sequence -in aggregate (n=27), these variants confer an 136 estimated 10-fold increase in risk of Acute CAD (95% CI: 3.9-25.6, p=1.4⨉10 -6 ). Though the role 137 of lipoprotein receptors in cholesterol metabolism is a well established mechanism of risk for 138 cardiovascular disease, LDLRAD3 is not known to participate in cholesterol metabolism. It is, 139 however, a receptor widely expressed throughout adult tissues which may participate in 140 proteolysis in the central nervous system 34, 35 . We therefore sought to replicate these findings 141
using two-sample mendelian randomization 36 on expression quantitative trait loci (eQTLs) from 142 CAD summary statistics from a CARDIoGRAMplusC4D meta-analysis 37 . We identify a nominally 143 significant protective effect between an eQTL increasing expression of Manhattan plots for (A) genomewide association of common copy number variants, and (B) genome-wide burden test of rare variants. (C) LocusZoom 38 of 9p23 CNV and summary statistics from meta-analysis of CAD 33 colored by marker LD with lead regional GWAS SNP (rs10809656) in HapMap 39 European samples.
149
We also find two significant associations for BMI, both deletions at chromosome 16p11. Phenome-wide associations for each of the CNVs at 16p11.2 further highlight changes in 180 biomarkers, biomeasures, and increased risk of common disease, consistent with high BMI over 181 the course of a lifetime (Figure 4 ). Genome-wide significant phenotypes for the 220kb CNV 182 recapitulate the established syndromic effects from early onset obesity. We observe significant 183 increases, on the order of one standard deviation, in weight, BMI, hip and waist circumference, 184 reticulocyte count, and comparative body size at age 10 for these individuals. Discussion: 193 194 In calling copy number variants and performing genetic association studies at scale from a large 195 cohort of array-genotyped individuals with richly annotated phenotype data, we provide a 196 portrait of the phenome-wide burden of genomic copy number variation. Our study has significant limitations which inform our analysis. While arrays are an inexpensive 206 way to genotype large cohorts, permitting straightforward algorithms to infer the presence of 207 structural variation, the resulting CNV calls are limited by the density and placement of markers 208 across chromosomes. For UK Biobank genotyping arrays in particular, there are large portions 209 of genomic sequence with low marker density (in particular near centromeric regions) which 210 bias our resulting genotype calls away from such regions. Array-derived CNV calls also suffer 211 from limitations, in their inability to differentiate other structural events like inversions or 212 translocations, or to determine breakpoint position at base-pair resolution. Complicating these 213
barriers is the fact that our sample was genotyped on two distinct arrays, which may cause 214 identical CNVs to present with different breakpoints across individuals in the call set. Our choice 215
to present gene-level burden tests which include the vast majority of variants included in our 216 CNV GWAS was informed by this realization. 217 218
Our associations are also heavily impacted by a known "healthy-cohort" bias, which results in 219 null results for several phenotypes with known genetic contributions; notably, there are no hits in 220 our burden tests for cancers other than leukemia and lymphomas. With this in mind, our 221 constraint scores constitute a sobering observation of genetic survivorship bias. Estimates of 222 gene-level intolerance to structural variation are derived from people who did not enroll in UK 223
Biobank; the absence of individuals who were not healthy enough to participate or did not 224 survive until age 40 constitutes a enrollment bias against severe early-onset disease. We take 225 this opportunity to honor these non-participating individuals and their implicit contribution to our 226 understanding of genetic disease. The observation of selection bias colors the interpretation of 227 genetic findings from UK Biobank in general, as the cohort is relatively depleted of disease of 228 early-onset morbidity and mortality and any genetic variation associated with these diseases will 229 likewise be difficult to detect. While UK Biobank is unprecedented in size, scope, and scientific 230 yield, our data illustrate that the anticipated findings from the proliferation of large biobank 231 studies around the world will be influenced by implicit and explicit barriers to participation. 232 233
Despite selection against high-penetrance alleles causing early-onset disease, we detect a 234 novel and strong association for coronary artery disease at LDLRAD3. While this locus has prior 235 putative association with bone mineral density 43 , existing large-scale GWAS do not detect a 236 strong association with coronary artery disease or established cardiometabolic risk-factors. 237
However, the absence of gene level intolerance to truncating and missense variation in 238
LDLRAD3 does not suggest a compelling rationale for important biological function or role in 239 disease. In our study, CNVs at this locus are associated with some established cardiometabolic 240 risk factors, such as diabetes onset, smoking status, and arterial stiffness, but not obesity or 241
other fat-related phenotypes ( Figure S6 ). Consistent with our findings that a decrease in 242
LDLRAD3 dosage increases the risk of disease, a strong eQTL increasing LDLRAD3 243 expression decreases the risk of disease when used as an instrument in a two-sample 244 mendelian randomization in a large-scale study of coronary artery disease. data from all statistical tests described here, as well as more thorough documentation on 306 phenotyping, will be available on the Global Biobank Engine 14 (biobankengine.stanford.edu) and 307
can be found in related publications 48 . 308 309
CNV calling in UK Biobank: 310 311
Methods for genetic data acquisition and quality control as performed by the UK Biobank have 312 been previously described 13 . In brief, two similar arrays were used for targeted genotyping 313
within the study population: the UK BiLEVE Axiom Array (n=49,950) by Affymetrix and the UK 314
Biobank Axiom Array (n=438,427), which was custom-designed by Applied Biosystems. 315
Samples and array markers were subject to threshold-based filtration and quality control prior to 316 public release. Specifically, markers were tested for discordance across control replicates, 317
departures from Hardy-Weinberg equilibrium, as well as effects due to batch, plate, array, and 318 sex; affected markers were set as missing in affected batches or removed. Similarly, samples 319
were tested for missingness (>5%) and heterozygosity across a set of high-quality markers, but 320 samples identified as low quality (n=968) were not excluded. We also chose to include these 321 samples in this analysis, considering that large structural variants may have been responsible 322
for their poor quality with respect to metrics used for filtration. 323 324 We used PennCNV v1.0.4 15 to call CNVs within each of the 106 genotyping batches from UK 325
Biobank. We first estimate genomic runs of heterozygosity (RoH) for each sample using a 326 previously developed pipeline in PLINK 49,50 using the --homozyg option. We then select n=100 327 samples with total RoH covering less than 20MB to train a hidden markov model (HMM) of copy 328 state on each chromosome. HMM training was initialized with conditions optimized for 329
Affymetrix arrays (affygw6.hmm), provided in PennCNV resources. We used the general calling 330 mode, which performs likelihood-based testing for copy-number state (CN=0,1,2,3,4) at each 331 input marker using its log-normalized signal intensity and allele balance in a given sample. We 332 also apply adjustment for GC content across sites using waviness factor correction 51 . While correlation between constraint measures across datasets is non-random, we suspect cohort-specific effects and varying definitions of genic burden of variation drive these departures. As a cohort of predominantly healthy adults, intolerance to variation in UK Biobank constraint is driven by severe early onset disease, while the same measures in ExAC/gnomAD, whose samples have a more diverse age range and relatively higher of burden of disease, highlight genes involved with fundamental biological processes whose loss of function likely confer phenotypic consequences causing embryonic lethality. Figure S6 : LDLRAD3 burden test PheWas. Significant (p < 10 -3 ) associations between regularized burden tests for LDLRAD3 CNV and phenotypes. We highlight quantitative traits with n > 15,000 observations and binary traits with n > 100 cases. Traits are grouped by data type then sorted by p-value (left). Log-odds ratio and standardized betas (right; for binary and quantitative traits, respectively) align with trait names on the y-axis, with the horizontal dashed line separating positive and negative direction of association. 410 411 412 413
